1.1 Research Scope and Index

1.2 Research Methodology

1.3 Assessment of Top Technologies: 2014 and 2015

1.4 Better Outcomes in Healthcare through Innovation

1.5 Healthcare Will Become Increasingly Personalized

1.6 Cancer Immunotherapy Is an Exciting Research Area of New Cancer Treatments

2.1 Biosimilars Are Poised for Steady and Long-term Growth

2.2 Patenting Is Largely Focused on Bio Manufacturing Capabilities

2.3 Production Process and Technical Needs Are Complex

2.4 Pharma Companies Have a Strong Hold on Biosimilars Industry

2.5 European Regulatory Legislations Most Convenient for Developers

2.6 Europe Leads with the Highest Number of Approved Biosimilars

2.7 Key Questions for Strategy Planning

3.1 Early Detection and Better Treatments Possible Due to Cancer Screening

3.2 United States Leads in Cancer Screening Innovations

3.3 Increase in Funding for Liquid Biopsy

3.4 Next-generation Sequencing Is a Major Enabling Technology

3.5 Novel Screening Techniques Will Have an Impact across the Healthcare Value Chain

3.6 Higher Adoption Rates Witnessed in Developed Economies

3.7 Key Questions for Strategy Planning

4.1 Agbio, Human Therapeutics, R&D, and Industrial Applications Impacted by Molecular Scissors

4.2 Nucleases Used in Genome Editing Have Varying Technical Capabilities

4.3 Steady Growth in Patent Filing Related to Genome Editing

4.4 CRISPR Patent Battle Will Impact the Gene Editing Market

4.5 High Series Funding from Venture Capitals for Genome Editing Innovators

4.6 Human Therapeutics Is a Key Application Area

4.7 North America and Europe Are Dominating the Market

4.8 Key Questions for Strategy Planning

5.1 Success in Next-gen Stem Cells Demands Impeccable Interaction among Stakeholders

5.2 Clinical Trials and Stem Cell Banking Services Are Spectacularly Driving the Market

5.3 The Advent of Cell Reprogramming Has Reshaped IP Landscape

5.4 Strong Governmental Support and International Collaboration Is Driving Opportunities

5.5 Next-gen Stem Cell Technology Is Impacting the Industry at All Decision Levels

5.6 Every Region Is Geared toward Innovation and Commercialization

5.7 Clinical Translation Is a Major Concern for All Science Driven Establishments

5.8 Key Questions for Strategy Planning

6.1 Therapeutic Antibodies Paving the Way for the Precision Medicine Era

6.2 An Unprecedented Search for Access to the Latest Advances in Monoclonal Antibodies

6.3 Patents of Top 3 Patent Holders Constitute One-third of Total Published Patents

6.4 Private Investors and Funding Organizations Heavily Focused on Antibody Therapy

6.5 Immuno-oncology Leading Principal Deals in Antibody Therapeutics

6.6 Unprecedented Race to Reach the Top Spot in the Market

6.7 Strong Focus on Clinical Translation Evidenced through Creation of Companies

6.8 Key Questions for Strategy Planning

7.1 3D Scaffolds a Major Driver for the Growth of 3D Cell Culture Tools

7.2 US Leads 3D Scaffolds Innovation Landscape with Most Patent Applications

7.3 NIAMS Is a Major Funding Proponent for Development

7.4 Functional Characteristics of 3D Scaffolds Impact Tissue Engineering

7.5 Key Stakeholders Are Focusing on the Potential Their Products Have for In Vitro Laboratory Applications

7.6 Europe Leads All Regions with Highest Adoption of 3D Cell Culture Systems

7.7 Key Questions for Strategy Planning

8.1 Cancer Immunotherapies Riding the PD-1 Wave

8.2 European and Asian Companies Lead the Innovation Landscape

8.3 Moderna Therapeutics Leads the Venture Landscape

8.4 Most Cancer Immunotherapies Target Immune Checkpoint Regulators

8.5 Lung Cancer Is a Major Application Area for Cancer Immunotherapy

8.6 The United States and Europe Lead Cancer Immunotherapy Markets

8.7 Key Questions for Strategy Planning

9.1 Advances in HTGS Driven by the Race to Develop Low-priced Platforms

9.2 China Leads the HTGS Innovation Landscape

9.3 Cancer Is a Clinical Hot Spot for HTGS-related Funding Activities

9.4 Technology Capabilities and Affordability Fuel Sequencing Innovations

9.5 HTGS May Have Increased Diagnostic Applications in the Future

9.6 The United States Leads the HTGS Markets

9.7 Key Questions for Strategy Planning

10.1 Transdermal Drug Delivery System Technology Evolution

10.2 Translation to Medical Practice Driving Principal Innovations

10.3 Technological Trends Highly Reflected in Patent Analysis

10.4 Strong Commitment of Both Public and Private Sources

10.5 Microneedles Leading the Technological Space

10.6 Worldwide Concerns about Disorders Drive Developments in Transdermal Drug Delivery

10.7 Companies Focused on Solutions in Clinical Practice

10.7 Companies Focused on Solutions in Clinical Practice (continued)

10.7 Companies Focused on Solutions in Clinical Practice (continued)

10.8 Key Questions for Strategy Planning

11.1 Smart Nanotechnology Enabling Next-gen Healthcare Solutions

11.2 More Than Six Hundred Nanomedicines in Clinical Development

11.3 Top-tier Companies Own a Pipeline of Breakthrough Nanotherapeutics

11.4 Governments Have Been Aware of the Potential of Nanomedicine for Nearly Two Decades

11.5 Nanomedicine and Nanobiotechnology Evolution as a Proof of Technology Synergy

11.6 Nanomedicine Evolution From Nanostructures to Precision Therapeutic Vehicles

11.7 Nanomedicine Shifting Business Models for Global Success

11.8 Top-tier Pharmaceutical Companies’ Products Reaching the Market

11.9 Key Questions for Strategy Planning

Legal Disclaimer

12.1 The Frost & Sullivan Story

12.2 Value Proposition: Future of Your Company & Career

12.3 Global Perspective

12.4 Industry Convergence

12.5 360º Research Perspective

12.6 Implementation Excellence

12.7 Our Blue Ocean Strategy